Abstract
Hercules Capital will report second-quarter 2026 results on July 30, 2026 Post Market, with investors watching revenue momentum, margin resilience, and adjusted EPS versus a modestly rising consensus.
Market Forecast
The market’s baseline for the quarter points to total revenue of 145.48 million US dollars, implying year-over-year growth of 11.39%, and adjusted EPS of 0.485, indicating year-over-year growth of 2.92%. Forecasts for gross profit margin and net profit margin are not broadly published; given limited forward disclosure on margins, the near-term focus centers on revenue and earnings delivery.
The core revenue engine remains lending-related interest income, where stable portfolio yields and an active origination calendar suggest continued top-line support alongside relatively predictable expense run rates. Fee income is the most sensitive swing factor, with potential upside tied to repayments, refinancings, and transaction activity; last quarter, fee income contributed 5.13 million US dollars (YoY by segment not disclosed), providing a cushion to per-share earnings if early payoffs accelerate.
Last Quarter Review
In the prior quarter, Hercules Capital posted revenue of 141.54 million US dollars, a 100.00% gross profit margin, GAAP net income attributable to shareholders of 42.50 million US dollars, a 30.03% net profit margin, and adjusted EPS of 0.48, up 6.67% year over year.
One notable highlight was a narrow yet clean beat versus consensus: revenue exceeded estimates by roughly 0.30%, and adjusted EPS of 0.48 topped the 0.477 baseline.
Operating mix skewed toward core lending, with interest income of 136.40 million US dollars representing 96.37% of total revenue and fee income of 5.13 million US dollars representing 3.63%; year-over-year contributions by segment were not disclosed in the company’s summary breakout.
Current Quarter Outlook
Main lending business
Hercules Capital’s quarter is set up around the durability of its core lending revenue stream, where guidance and independent estimates converge on a moderate top-line expansion to 145.48 million US dollars. For this model, the trajectory of average earning assets, portfolio yields, and borrower activity across the book should drive revenue cadence more than one-off items. Recent activity suggests origination and funding momentum into the life sciences and technology ecosystems remains intact: the company arranged up to 165 million US dollars for Beren Therapeutics on June 10, 2026, and supported a strategic credit facility of up to 200 million US dollars for 4D Molecular Therapeutics on June 29, 2026; combined with announced structures for borrowers like Lexicon Pharmaceuticals and Senseonics earlier in the quarter, these add to forward interest accruals as draws materialize.
The interplay between new fundings and early payoffs will likely shape both revenue and fee recognition. If early repayments remain orderly rather than spiking, the revenue mix should skew more toward recurring interest, which typically improves predictability for adjusted EPS. Conversely, a pickup in exits or refinancings can create short, favorable bursts of fee income but introduce timing variance. The company’s 100.00% gross margin profile underscores that operating cost pressure is not embedded in cost of goods sold; instead, earnings sensitivity resides in net financing costs, credit-related items, and fee variability. For net income translation, the reported 30.03% net margin from last quarter provides a recent reference point; margin direction this quarter will reflect revenue scale, funding costs, and any credit-driven items affecting net results.
Funding structure and cost of debt are a secondary, but relevant, overlay on the lending economics. While the newly priced 6.300% notes due July 2031 (325 million US dollars, priced on July 22, 2026, with an expected close on July 24, 2026) fall largely outside the quarter’s P&L window, investors may seek commentary on how this capital will be deployed and how it may influence the run-rate interest expense into the second half of 2026. If management outlines a plan to rotate short-term liabilities into this longer-dated issuance while sustaining origination pace, the interest expense headwind could be offset by portfolio growth and yield preservation. Altogether, steady interest income growth against a disciplined funding strategy and measured prepayment environment would support delivery against the 11.39% year-over-year revenue growth and 2.92% year-over-year EPS growth embedded in current expectations.
Most promising revenue contributor: Fee income
Fee income, though smaller in absolute terms, is the most volatile and potentially accretive lever for upside versus consensus. Last quarter it contributed 5.13 million US dollars, equivalent to 3.63% of total revenue, and it typically benefits from repayments, upsizes, syndications, and other transactional catalysts; year-over-year detail by segment was not disclosed, but the qualitative drivers are clear. Given multiple announced facilities in the quarter and ongoing portfolio activity, the setup supports periodic bursts in fee recognition if borrowers refinance or draw opportunistically, although timing is inherently lumpy.
In the context of a 145.48 million US dollars revenue baseline, incremental fee inflows can translate with high drop-through into adjusted EPS, especially because core operating cost absorption is already reflected in the recurring run rate. If prepayment activity shows a slight pickup versus the first quarter without significantly denting interest accrual days, the net effect could be positive on both revenue and earnings. Management commentary on pipeline maturity, expected repayments, and any large-ticket amendments will be especially relevant to triangulate the magnitude of fee income this quarter. An environment where originations remain healthy and early payoffs are selective rather than broad-based would likely allow fee income to complement, rather than substitute, interest revenue, supporting the 0.485 adjusted EPS baseline.
Key stock price drivers this quarter
Earnings-per-share delivery relative to the 0.485 baseline is the primary share-price catalyst, with investors parsing the composition of revenue between recurring interest and episodic fees. A print that matches or slightly exceeds the 2.92% year-over-year EPS growth embedded in consensus, with limited reliance on one-offs, would typically be taken as evidence of earnings quality. Conversely, a miss driven by weaker fee income without compensating interest growth could pressure sentiment even if the full-year trajectory remains intact.
Net asset value disclosure and credit quality updates will be closely monitored in conjunction with the company’s preliminary June 30, 2026 estimate that placed NAV per share between 12.10 US dollars and 12.20 US dollars. Confirmation within that range, or constructive commentary regarding realized/unrealized marks and non-accrual trends, would reinforce balance sheet stability. If management reports stable non-accruals and no material idiosyncratic impairments, investors may place greater weight on the income statement and origination signals over valuation adjustments. The credit rating affirmation at BBB (high) with a Stable trend on March 4, 2026 provides an additional frame of reference around long-term funding flexibility, which can influence both growth capacity and required return assumptions.
Cost of capital and funding mix are the third determinant for the stock near the print. While the 6.300% notes due 2031 will not affect the second quarter’s interest expense, the incremental carry into the second half of 2026 will be part of the forward narrative. Investors may seek clarity on how the proceeds will be allocated across new and existing commitments and whether any near-term refinancing actions could neutralize the cost step-up. Clear articulation of matching assets and liabilities—keeping duration and rate exposure aligned—can mitigate concerns about net interest margin trajectory as policy rates evolve, anchoring valuation multiples around sustainable net income rather than transient spread variance.
Analyst Opinions
Among the preview and rating updates collected within the review window, the balance of opinion is bullish. Based on identifiable equity-research stances tied to the period, the ratio of bullish to bearish views is 100% to 0% (neutral opinions are excluded from this ratio). The most explicit positive call came from Ladenburg Thalmann & Co., which reaffirmed a Buy rating and set a 22.00 US dollars price target. While specific quarterly modeling details were not disclosed in their public summary, the maintained Buy stance into the second quarter underscores confidence that the company’s adjusted EPS and revenue cadence are tracking within a constructive range.
The bullish case emphasizes four factors going into July 30, 2026. First, adjusted EPS of 0.48 last quarter, with 6.67% year-over-year growth, indicates that earnings quality and scale are moving in the right direction, providing a reasonable base for the 0.485 forecast this quarter. Second, revenue of 141.54 million US dollars last quarter, up 18.43% year over year, offers evidence that the top line can absorb variability in fees and still support high incremental margins, consistent with the 100.00% gross margin profile. Third, the origination calendar remains active, as seen in announced facilities with Beren Therapeutics and 4D Molecular Therapeutics and other borrowers, which should underwrite sustained interest accruals across the coming quarters. Fourth, the recent pricing of 325 million US dollars in 6.300% notes due 2031, though outside the second quarter’s P&L, demonstrates ongoing access to term funding and provides capacity to support commitments without undue balance-sheet strain.
Supportive context also comes from the investment-grade outlook affirmed at BBB (high) with a Stable trend on March 4, 2026, which aligns with a funding profile capable of backing incremental originations at a measured cost. Bulls argue that if the company confirms a NAV range around 12.10 US dollars to 12.20 US dollars for June 30, 2026, and if credit quality remains steady with limited non-accrual movement, the valuation framework should center on dependable net income rather than mark-to-market variability. In that setup, the 11.39% year-over-year revenue growth and 2.92% year-over-year adjusted EPS growth embedded in the quarter’s consensus could be met or modestly exceeded, with fee income acting as a potential upside lever.
The constructive view ultimately hinges on execution—delivering a clean print with limited one-offs, a stable NAV bridge, and a clear funding roadmap that contextualizes the new 2031 notes. If those boxes are checked, bullish analysts expect the stock to respond to confirmation of steady earnings power. In this light, the majority stance remains favorable heading into July 30, 2026, anchored by the prior quarter’s performance, visible origination activity, and a balance sheet and funding position that appear aligned with near-term growth plans.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments